Treatment of an Elderly Patient with Acute Myeloid Leukemia and Invasive Pulmonary Aspergillosis Infection with Combined Allogeneic Hematopoietic Stem Cells Microtransplantation and Voriconazole

被引:3
作者
Nie, Weiye [1 ,2 ]
Huang, Qin [1 ,2 ]
Chen, Yongsheng [1 ]
Yin, Xiaolin [1 ]
机构
[1] Peoples Liberat Army, Dept Haematol, Hosp 303, Plant Rd 52, Nanning 530021, Guangxi, Peoples R China
[2] Guilin Med Univ, Guilin, Guangxi, Peoples R China
关键词
Microtransplantation; Invasive aspergillosis infection; Leukemia;
D O I
10.1007/s12288-015-0601-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Invasive aspergillosis infection (IF) in patients with hematologic malignancies is common. Prognosis of IF in patients with acute myeloid leukemia (AML) not responsive to chemotherapy is very poor, especially when neutropenia is duration. Fractional HLA haplo-identical mobilized neutropenia peripheral blood stem cell (PBSC) transfusion, which was defined as micro-transplantation, was recently adopted in treatment of elder patients with AML and shown to be effective in fasting hemopoiesis recovery. Here we report the outcome of an elderly patient with AML accompanying IF treated with microtransplantation and voriconazole. The patient (female, age 62) was diagnosed relapsed AML accompaning suspected invasive fungal infection. She refused to accept further chemotherapy. PBSC from her daughter were collected and transfused fractionally. Voriconazole was used for anti-aspergillosis treatment. After stem cell infusions, the patient's neutrophil count increased, and platelet transfusion interval extended from 3-4 to 10-14 days. Lung CT indicated that the lesions were significantly absorbed. The patient survived for 257 days. We concluded that for elderly patients with AML and accompanying IF who are not eligible for chemotherapy, microtransplant may be beneficial for improving the efficacy of anti-fungal treatment.
引用
收藏
页码:S56 / S58
页数:3
相关论文
共 36 条
  • [31] Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan
    Oran, Betul
    Giralt, Sergio
    Saliba, Rima
    Hosing, Chitra
    Popat, Uday
    Khouri, Issa
    Couriel, Daniel
    Qazilbash, Muzaffar
    Anderlini, Paolo
    Kebriaei, Partow
    Ghosh, Shubhra
    Carrasco-Yalan, Antonio
    de Meis, Ernesto
    Anagnostopoulos, Athanasios
    Donato, Michele
    Champlin, Richard E.
    de Lima, Marcos
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (04) : 454 - 462
  • [32] Cytoreductive treatment with clofarabine/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome
    Buchholz, Stefanie
    Dammann, Elke
    Stadler, Michael
    Krauter, Juergen
    Beutel, Gernot
    Trummer, Arne
    Eder, Matthias
    Ganser, Arnold
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 88 (01) : 52 - 60
  • [33] Correlation Between CD200 Expression on Leukemic Stem Cells and Response to Treatment in De novo Adult Acute Myeloid Leukemia Patients
    Hassan, Nouran
    Ibrahim, Tamer
    Nabeeh, Nermeen
    Abdelfatah, Rana
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S264 - S264
  • [34] LY86, LRG1 and PDE9A genes overexpression in umbilical cord blood hematopoietic stem progenitor cells by acute myeloid leukemia (M3) microvesicles
    Farnaz Razmkhah
    Sorayya Ghasemi
    Masoud Soleimani
    Sedigheh Amini Kafi-abad
    Experimental Hematology & Oncology, 8
  • [35] LY86, LRG1 and PDE9A genes overexpression in umbilical cord blood hematopoietic stem progenitor cells by acute myeloid leukemia (M3) microvesicles
    Razmkhah, Farnaz
    Ghasemi, Sorayya
    Soleimani, Masoud
    Kafi-abad, Sedigheh Amini
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2019, 8 (01)
  • [36] HLA-mismatched micro-transplantation as post-remission treatment compared to autologous hematopoietic stem cell transplantation or consolidation with single agent cytarabine for favorable-or intermediate-risk acute myeloid leukemia
    Tao, Shandong
    Zhou, Dan
    Song, Lixiao
    Deng, Yuan
    Chen, Yue
    Ding, Banghe
    He, Zhengmei
    Wang, Chunling
    Yu, Liang
    HEMATOLOGY, 2023, 28 (01)